Cargando…

Anti-angiogenic alternatives to VEGF blockade

Angiogenesis is a major requirement for tumour formation and development. Anti-angiogenic treatments aim to starve the tumour of nutrients and oxygen and also guard against metastasis. The main anti-angiogenic agents to date have focused on blocking the pro-angiogenic vascular endothelial growth fac...

Descripción completa

Detalles Bibliográficos
Autores principales: Khan, Kabir A., Bicknell, Roy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Netherlands 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4761368/
https://www.ncbi.nlm.nih.gov/pubmed/26620208
http://dx.doi.org/10.1007/s10585-015-9769-3
_version_ 1782416967048626176
author Khan, Kabir A.
Bicknell, Roy
author_facet Khan, Kabir A.
Bicknell, Roy
author_sort Khan, Kabir A.
collection PubMed
description Angiogenesis is a major requirement for tumour formation and development. Anti-angiogenic treatments aim to starve the tumour of nutrients and oxygen and also guard against metastasis. The main anti-angiogenic agents to date have focused on blocking the pro-angiogenic vascular endothelial growth factors (VEGFs). While this approach has seen some success and has provided a proof of principle that such anti-angiogenic agents can be used as treatment, the overall outcome of VEGF blockade has been somewhat disappointing. There is a current need for new strategies in inhibiting tumour angiogenesis; this article will review current and historical examples in blocking various membrane receptors and components of the extracellular matrix important in angiogenesis. Targeting these newly discovered pro-angiogenic proteins could provide novel strategies for cancer therapy.
format Online
Article
Text
id pubmed-4761368
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Springer Netherlands
record_format MEDLINE/PubMed
spelling pubmed-47613682016-03-01 Anti-angiogenic alternatives to VEGF blockade Khan, Kabir A. Bicknell, Roy Clin Exp Metastasis Review Angiogenesis is a major requirement for tumour formation and development. Anti-angiogenic treatments aim to starve the tumour of nutrients and oxygen and also guard against metastasis. The main anti-angiogenic agents to date have focused on blocking the pro-angiogenic vascular endothelial growth factors (VEGFs). While this approach has seen some success and has provided a proof of principle that such anti-angiogenic agents can be used as treatment, the overall outcome of VEGF blockade has been somewhat disappointing. There is a current need for new strategies in inhibiting tumour angiogenesis; this article will review current and historical examples in blocking various membrane receptors and components of the extracellular matrix important in angiogenesis. Targeting these newly discovered pro-angiogenic proteins could provide novel strategies for cancer therapy. Springer Netherlands 2015-11-30 2016 /pmc/articles/PMC4761368/ /pubmed/26620208 http://dx.doi.org/10.1007/s10585-015-9769-3 Text en © The Author(s) 2015 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Review
Khan, Kabir A.
Bicknell, Roy
Anti-angiogenic alternatives to VEGF blockade
title Anti-angiogenic alternatives to VEGF blockade
title_full Anti-angiogenic alternatives to VEGF blockade
title_fullStr Anti-angiogenic alternatives to VEGF blockade
title_full_unstemmed Anti-angiogenic alternatives to VEGF blockade
title_short Anti-angiogenic alternatives to VEGF blockade
title_sort anti-angiogenic alternatives to vegf blockade
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4761368/
https://www.ncbi.nlm.nih.gov/pubmed/26620208
http://dx.doi.org/10.1007/s10585-015-9769-3
work_keys_str_mv AT khankabira antiangiogenicalternativestovegfblockade
AT bicknellroy antiangiogenicalternativestovegfblockade